Join our mailing list and receive the monthly BioVox newsletter for free!

RELATED ARTICLES
Belgian scientists in Nature with cancer breakthrough

Scientists Peter Carmeliet and Sarah-Maria Fendt (KU Leuven/VIB) published in the prestigious Nature journal on their fundamental breakthrough in …


ThromboGenics and VIB found oncology company

Oncurious is a new oncology company that will perform clinical trials for the development of TB-403. This compound is a new promising agent for…


Congrats to Biocartis!

The Mechelen-based biotech company Biocartis starts its IPO adventure. The demand for shares was 6,5 times higher than the offer. Biocartis gather…

POPULAR TAGS

Diagnosed with lung cancer

Written by AVG on in the category Insights with the tags .


A patient diagnosed with lung cancer should brace for the worst. Prognosis is often very disappointing. While in many cancers early diagnosis and treatment is key, lung cancer patients experience regular relapses, even when diagnosed early.

Most of the time this can be controlled with chemotherapy, albeit temporarily. After that, immunotherapy offers some hope, but only for 20% of the patients. New, more advanced treatment technology is badly needed.

Karim Vermaelen, pulmonary physician and thoracic oncologist at UZ Gent, is on a mission. He and his team are focused on saving more people and investigate the interactions between lung cancer and the immune system, with a special focus on dendritic cells.

A therapeutic vaccine

Therapeutic vaccination against cancer has proven to be challenging. The vaccine intervention must combat an immune system that has been restrained to sustain the disease in a misguided attempt at self-tolerance. Nevertheless, recent clinical results indicate that the era of successful therapeutic vaccination has arrived. Karim and his team are ready to bring their vaccine against lung cancer into the clinic.

'We are focusing on dendritic cells because they can function as sentinels and alert T-lymphocytes when tumors develop. We uncovered how lung tumors corrupt the function of the dendritic cells and escape immune control by reprogramming the micro-RNA repertoire of the dendritic cells. The micro-RNA signature of these corrupt cells predicts a worse outcome in lung cancer patients. We think that interfering with the surge of bad micro-RNAs within dendritic cells can provide a novel way to restore proper anti-tumor immunity’.

‘For now, we are exploring the therapeutic potential of immunostimulatory dendritic cells generated in vitro from patient blood. By loading these cells with mRNA prepared from the patient’s own tumor, or mRNA encoding a highly expressed and immunogenic set of cancer antigens, we are developing a cellular vaccine. In vitro, the vaccine has all the characteristics to induce a strong immune response and tackle the tumor cells that now escape. We are preparing the dossier for approval by the FAGG (the Belgian Federal Agency for Medicines and Health Products). We are keen to get the first trials started with a limited number of patients to establish safety and biological activity. This will allow us to move quickly to metastatic cancer patients’.

Immunotherapy has already delivered fantastic results.

 

Immunotherapy: not a one-trick pony

Karim is in it for the long run. ‘I am a physician and researcher. I am very focused on delivering technologies that work and can save patients’ lives. We have a very solid strategy and the prototype vaccine has been very well characterized, passed all the preclinical tests and we know we can produce sufficient cells'.
‘Immunotherapy has already delivered fantastic results. Especially for cancers where there was no alternative treatment. But some tumors present a very complex immune pattern, or appear as immunological “deserts”, and we don’t know yet if we can find their immunological key. I hope we can help patients with metastatic lung cancer. If we can control spread and growth of the tumors, we can save lives. That’s why we do it’.

Karim is a keynote speaker at the ‘kankercongres’ in Ghent, October 21. He will present an overview of immunotherapy and the impact on patients’ lives.

Read more about: .

RELATED ARTICLES
Belgian scientists in Nature with cancer breakthrough

Scientists Peter Carmeliet and Sarah-Maria Fendt (KU Leuven/VIB) published in the prestigious Nature journal on their fundamental breakthrough in …


ThromboGenics and VIB found oncology company

Oncurious is a new oncology company that will perform clinical trials for the development of TB-403. This compound is a new promising agent for…


Congrats to Biocartis!

The Mechelen-based biotech company Biocartis starts its IPO adventure. The demand for shares was 6,5 times higher than the offer. Biocartis gather…

POPULAR TAGS

Sign up to our Mailing List to receive updates
of our latest News, Events & Magazines

GSK Janssen KU Leuven Itera Life Science UGent Flanders.bio Biowin Turnstone V-Bio Ventures XpandInnovation

ABOUT BIOVOX - Sharing Life Sciences Innovations

BioVox showcases interesting life sciences breakthroughs for and from Belgian innovators. Through our partnership with BioCentury we share relevant worldwide innovations and business updates while our local journalists focus on regional highlights. 

Interested to get involved? Get in touch! We are looking for content, writers and partners! Blogs are available for research institutes, companies and freelance experts.

You want to reach out to the biotechnology and life sciences community, targetting selected audiences? Discover our sponsor and publication opportunities as well as tailored packages!

Contact BioVox via news@biovox.be or by completing the contact form.